Patents by Inventor Thomas CATELAIN

Thomas CATELAIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors
    Patent number: 11472806
    Abstract: The present invention provides novel heterocyclic compounds of the general formula (I), including novel compounds of formula (Ia), and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) or (Ia) and the pharmaceutical compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. The compounds of formula (I) or (Ia) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: October 18, 2022
    Assignee: Domain Therapeutics
    Inventors: Anne-Laure Blayo, Thomas Catelain, Ismet Dorange, Cédric Genet, Baptiste Manteau, Stanislas Mayer, Stephan Schann
  • 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20210380606
    Abstract: The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.
    Type: Application
    Filed: October 22, 2019
    Publication date: December 9, 2021
    Applicant: Merck Patent GmbH
    Inventors: Anne-Laure BLAYO, Baptiste MANTEAU, Ismet DORANGE, Stanislas MAYER, Stephan SCHANN, Thomas CATELAIN
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS
    Publication number: 20200140438
    Abstract: The present invention provides novel heterocyclic compounds of the general formula (I), including novel compounds of formula (Ia), and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) or (Ia) and the pharmaceutical compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. The compounds of formula (I) or (Ia) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.
    Type: Application
    Filed: May 14, 2018
    Publication date: May 7, 2020
    Inventors: Anne-Laure BLAYO, Thomas CATELAIN, Ismet DORANGE, Cédric GENET, Baptiste MANTEAU, Stanislas MAYER, Stephan SCHANN